A new clinical trial shows CBP-1018, an experimental bi-ligand–drug conjugate, could be a promising treatment for mCRPC, as presented at ASCO GU 2025.
Among 76 patients treated at effective doses, 88% had disease control, 20% had significant tumor shrinkage, and 60% saw tumor size reduction.
At seven months, 70% of patients remained progression-free, with 60% still benefiting after a year. Side effects were mild and manageable. Unlike similar drugs, severe nerve damage and vision issues were rare.
Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy
Challenges from the Increased Spread of COVID-19
New cancer treatment immuno therapy combined with guadecitabine in lung, breast, prostate bowel cancer makes cancer visible to immune sys